aurapten and Hemolysis

Auraptene (AUR), a natural bioactive prenyloxy coumarin, is a highly pleiotropic molecule that can bind to the MT1 receptor and can effectively reduce the proliferation and migration of breast cancer cells. Cisplatin (CDDP), as the first synthetic platinum-based anticancer drug, is widely used in the clinic due to its definite mechanism and therapeutic effect on diverse tumors. However, both of AUR and CDDP exhibit some disadvantages when used alone, including poor solubility, low bioavailability, lack of selectivity and systemic toxicity when they are used singly.. Therefore, the biodegradable materials hyaluronic acid (HA) and β-cyclodextrin derivative (mono-(6-amino-mono-6-deoxy)-β-CD, CD) were employed as carriers to load AUR and CDDP to form nanogel (. With the help of the CDDP-crosslinked CD-loaded structure, the newly synthesized nanogel exhibited excellent physiological stability and fluorescence effects. The release of AUR and CDDP was affected by the pH value, which was beneficial to the selective release in the tumor microenvironment. Cell experiments in vitro demonstrated that the nanogel could be selectively internalized by MCF-7 cells and exhibited low cytotoxicity to HK-2 cells. Antitumor experiments in vivo showed that the nanogel have better antitumor effects and lower systemic toxicity.. Based on these, the nanogel loaded with AUR and CDDP have the potential for targeted delivery against breast cancer.

Topics: Animals; Breast Neoplasms; Cell Death; Cisplatin; Coumarins; Drug Carriers; Drug Liberation; Endocytosis; Female; Hemolysis; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanogels; Organ Specificity; Particle Size; Polyethylene Glycols; Polyethyleneimine; Rabbits; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared